Tapentadol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tapentadol" in English language version.

refsWebsite

Global rank English rank

52nih.gov

4^th place

33doi.org

2^nd place

27web.archive.org

1^st place

4drugs.com

399^th place

333^rd place

3who.int

195^th place

302^nd place

2nps.org.au

low place

2healthdirect.gov.au

low place

2semanticscholar.org

11^th place

8^th place

2fda.gov

447^th place

338^th place

2usdoj.gov

2,755^th place

1,753^rd place

1medlineplus.gov

1,581^st place

1,299^th place

1in.gov.br

3,151^st place

5,932^nd place

1europa.eu

68^th place

117^th place

1medicinescomplete.com

low place

1cdc.gov

218^th place

212^th place

1patents.google.com

1,182^nd place

725^th place

1nsw.gov.au

640^th place

382^nd place

1gov.uk

432^nd place

278^th place

1medscape.com

719^th place

636^th place

1worldcat.org

5^th place

1janssen.com

low place

1harvard.edu

18^th place

17^th place

1psychiatrist.com

low place

1handle.net

102^nd place

76^th place

1mayoclinic.org

1,610^th place

1,279^th place

1books.google.com

3^rd place

1wfsahq.org

low place

1unsw.edu.au

4,584^th place

3,029^th place

1prnewswire.co.uk

6,376^th place

4,260^th place

1jnj.com

low place

1genengnews.com

low place

6,625^th place

1thepharmaletter.com

low place

1iwpharmacy.com

low place

1fiercepharma.com

low place

8,921^st place

1tga.gov.au

3,984^th place

2,622^nd place

1legislation.gov.uk

809^th place

536^th place

1incb.org

low place

9,618^th place

1gazette.gc.ca

low place

1osf.io

7,153^rd place

4,975^th place

1banglanews24.com

4,869^th place

6,845^th place

banglanews24.com (Global: 4,869^th place; English: 6,845^th place)

"71 arrested in DMP's anti-narcotics drive". BanglaNews24.com (in Bengali). 2021-12-14. Archived from the original on 2021-12-30. Retrieved 2021-12-30.

books.google.com (Global: 3^rd place; English: 3^rd place)

Talley NJ, Frankum B, Currow D (10 February 2015). Essentials of Internal Medicine 3e. Elsevier Health Sciences. pp. 491–. ISBN 978-0-7295-8081-6.

cdc.gov (Global: 218^th place; English: 212^th place)

"CDC Opioid Calculator". 13 October 2022.

doi.org (Global: 2^nd place; English: 2^nd place)

Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, et al. (January 2010). "Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies". Pharmacotherapy. 30 (1): 25–34. doi:10.1592/phco.30.1.25. PMC 2888545. PMID 20030470.
Khaja M, Lominadze G, Millerman K (July 2017). "Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review". The American Journal of Case Reports. 18: 817–821. doi:10.12659/AJCR.904695. PMC 5536129. PMID 28729524.
Alshehri FS (2023-03-01). "Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings". Drug Design, Development and Therapy. 17 (2023): 851–861. doi:10.2147/dddt.s402362. PMC 10039632. PMID 36974332.
Dart RC, Bartelson BB, Adams EH (August 2014). "Nonmedical use of tapentadol immediate release by college students". The Clinical Journal of Pain. 30 (8): 685–692. doi:10.1097/AJP.0000000000000001. PMID 24042351.
Singh DR, Nag K, Shetti AN, Krishnaveni N (July 2013). "Tapentadol hydrochloride: A novel analgesic". Saudi Journal of Anaesthesia. 7 (3): 322–326. doi:10.4103/1658-354X.115319. PMC 3757808. PMID 24015138.
Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C (2010). "Dose conversion between tapentadol immediate and extended release for low back pain". Pain Physician. 13 (1): 61–70. doi:10.36076/ppj.2010/13/61. PMID 20119464.
Chang EJ, Choi EJ, Kim KH (July 2016). "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?". The Korean Journal of Pain. 29 (3): 153–157. doi:10.3344/kjp.2016.29.3.153. PMC 4942642. PMID 27413479.
Guillén-Astete CA, Cardona-Carballo C, de la Casa-Resino C (November 2017). "Tapentadol versus tramadol in the management of low back pain in the emergency department: Impact of use on the need for reassessments". Medicine. 96 (45) e8403. doi:10.1097/MD.0000000000008403. PMC 5690718. PMID 29137025.
Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, et al. (July 2012). "Mechanistic and functional differentiation of tapentadol and tramadol". Expert Opinion on Pharmacotherapy. 13 (10): 1437–1449. doi:10.1517/14656566.2012.696097. PMID 22698264. S2CID 24226747.
Tschentke TM, De Vry J, Terlinden R, Hennies HH, Lange C, Strassburger W, et al. (2006). "Tapentadol Hydrochloride". Drugs of the Future. 31 (12): 1053. doi:10.1358/dof.2006.031.12.1047744.
Kathiresan P, Pakhre A, Kattula D, Sarkar S (October 2019). "Tapentadol Dependence: A Case Series". The Primary Care Companion for CNS Disorders. 21 (5): 23400. doi:10.4088/PCC.19l02444. PMID 31682335.
Polati E, Canonico PL, Schweiger V, Collino M (2019-05-16). "Tapentadol: an overview of the safety profile". Journal of Pain Research. 12: 1569–1576. doi:10.2147/JPR.S190154. PMC 6529613. PMID 31190968.
Roulet L, Rollason V, Desmeules J, Piguet V (July 2021). "Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients". Drugs. 81 (11): 1257–1272. doi:10.1007/s40265-021-01515-z. PMC 8318929. PMID 34196947.
Oliveira M, Moisés MC, Dias EC, dos Santos MV, Schmidt AP (January 2024). "Treatment-emergent adverse events of tapentadol or oxycodone in pain management after orthopedic surgeries: A systematic review and meta-analysis of randomized clinical trials". JCA Advances. 1 (3) 100024. doi:10.1016/j.jcadva.2024.100024. ISSN 2950-5534.
Butler SF, McNaughton EC, Black RA (January 2015). "Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment". Pain Medicine. 16 (1): 119–130. doi:10.1111/pme.12524. PMID 25243972.
Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, et al. (April 2018). "Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System". The Journal of Pain. 19 (4): 439–453. doi:10.1016/j.jpain.2017.11.007. PMID 29224919.
Sharma M, Soni R (February 2018). "Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study". Scientific Reports. 8 (1) 2812. Bibcode:2018NatSR...8.2812S. doi:10.1038/s41598-018-21214-2. PMC 5809392. PMID 29434240.
Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I (January 2015). "Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain". Clinical Therapeutics. 37 (1): 94–113. doi:10.1016/j.clinthera.2014.07.005. PMID 25108647.
Vellucci R, Fornasari D (January 2023). "Appropriate use of tapentadol: focus on the optimal tapering strategy". Current Medical Research and Opinion. 39 (1): 123–129. doi:10.1080/03007995.2022.2148459. hdl:2434/948379. PMID 36427080.
Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, et al. (August 2014). "A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy". Diabetes Care. 37 (8): 2302–2309. doi:10.2337/dc13-2291. PMID 24848284.
Nossaman VE, Ramadhyani U, Kadowitz PJ, Nossaman BD (December 2010). "Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol". Anesthesiology Clinics. 28 (4): 647–666. doi:10.1016/j.anclin.2010.08.009. PMID 21074743.
Ramaswamy S, Chang S, Mehta V (May 2015). "Tapentadol--the evidence so far". Anaesthesia. 70 (5): 518–522. doi:10.1111/anae.13080. PMID 25866038.
Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T, et al. (April 2011). "Synergistic interaction between the two mechanisms of action of tapentadol in analgesia". The Journal of Pharmacology and Experimental Therapeutics. 337 (1): 312–320. doi:10.1124/jpet.110.175042. PMC 3364495. PMID 21262850.
Alshehri FS (2023). "Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings". Drug Design, Development and Therapy. 17: 851–861. doi:10.2147/DDDT.S402362. PMC 10039632. PMID 36974332.
Kokilambigai KS, Irina VM, Sheba Mariam KC, Adila K, Kathirvel S (September 2024). "Comprehensive overview of analytical and bioanalytical methodologies for the opioid analgesics - Tramadol and combinations". Anal Biochem. 692 115579. doi:10.1016/j.ab.2024.115579. PMID 38797485.
Chang EJ, Choi EJ, Kim KH (July 2016). "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?". The Korean Journal of Pain. 29 (3): 153–157. doi:10.3344/kjp.2016.29.3.153. PMC 4942642. PMID 27413479.
Roulet L, Rollason V, Desmeules J, Piguet V (July 2021). "Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients". Drugs. 81 (11): 1257–1272. doi:10.1007/s40265-021-01515-z. PMC 8318929. PMID 34196947.
Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ (May 2018). "Comparative pharmacology and toxicology of tramadol and tapentadol". European Journal of Pain. 22 (5): 827–844. doi:10.1002/ejp.1196. PMID 29369473.
Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K (2007). "Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects". European Journal of Drug Metabolism and Pharmacokinetics. 32 (3): 163–169. doi:10.1007/BF03190478. PMID 18062408.
Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS (2013-07-01). "Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects". Journal of Opioid Management. 9 (4): 291–300. doi:10.5055/jom.2013.0171. PMID 24353023.
Wiffen PJ, Derry S, Naessens K, Bell RF (September 2015). "Oral tapentadol for cancer pain". The Cochrane Database of Systematic Reviews. 2015 (9) CD011460. doi:10.1002/14651858.CD011460.pub2. PMC 6483480. PMID 26403220.
Vosburg SK, Beaumont J, Dailey-Govoni ST, Butler SF, Green JL (September 2020). "Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV)". Pain Medicine. 21 (9): 1891–1901. doi:10.1093/pm/pnz250. PMC 7553020. PMID 31617931.
Mukherjee D, Shukla L, Saha P, Mahadevan J, Kandasamy A, Chand P, et al. (March 2020). "Tapentadol abuse and dependence in India". Asian Journal of Psychiatry. 49 101978. doi:10.1016/j.ajp.2020.101978. PMID 32120298. S2CID 211834859. Archived from the original on 2021-12-20. Retrieved 2021-10-10.

drugs.com (Global: 399^th place; English: 333^rd place)

"Tapentadol (Monograph)". American Society of Health-System Pharmacists (AHFS). 19 April 2023 – via Drugs.com.
"Nucynta History". drugs.com. Archived from the original on April 12, 2015. Retrieved April 5, 2015.
"Nucynta (tapentadol) FDA Approval History – Drugs.com". www.drugs.com. Archived from the original on 2015-04-12. Retrieved 2016-03-09.
"FDA Approves Nucynta ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". Archived from the original on 2021-03-05. Retrieved 2018-01-23.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Active substance(s): tapentadol" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 21 July 2022. Archived (PDF) from the original on 2022-09-06. Retrieved 2022-09-06.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Nucynta Label" (PDF). Archived from the original (PDF) on 2021-03-30.
"Tapentadol Post Marketing Requirement" (PDF). Center for Drug Evaluation and Research (CDER). FDA. 4 November 2008.

fiercepharma.com (Global: low place; English: 8,921^st place)

"Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs". FiercePharma. 5 December 2017. Archived from the original on 2019-10-15. Retrieved 2019-10-15.

gazette.gc.ca (Global: low place; English: low place)

"Canada Gazette – Regulations Amending the Narcotic Control Regulations (Tapentadol) – (Archived)". Canada Gazette. Government of Canada, Public Works and Government Services Canada, Public Services and Procurement Canada, Integrated Services Branch, Canada. 29 July 2015. Archived from the original on 2016-03-13. Retrieved 2016-03-12.

genengnews.com (Global: low place; English: 6,625^th place)

Dutton G (1 June 2012). "Pain Management Market Ripe with Immediate Opportunities". Genetic Engineering & Biotechnology News. Archived from the original on 2018-09-23.

gov.uk (Global: 432^nd place; English: 278^th place)

"List of most commonly encountered drugs currently controlled under the misuse of drugs legislation". gov.uk. Retrieved 2024-11-23.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Vellucci R, Fornasari D (January 2023). "Appropriate use of tapentadol: focus on the optimal tapering strategy". Current Medical Research and Opinion. 39 (1): 123–129. doi:10.1080/03007995.2022.2148459. hdl:2434/948379. PMID 36427080.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Sharma M, Soni R (February 2018). "Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study". Scientific Reports. 8 (1) 2812. Bibcode:2018NatSR...8.2812S. doi:10.1038/s41598-018-21214-2. PMC 5809392. PMID 29434240.

healthdirect.gov.au (Global: low place; English: low place)

"Tapentadol". Health Direct. 23 October 2024 – via healthdirect.gov.au.
Health Direct (2024-10-23). "Tapentadol". www.healthdirect.gov.au. Retrieved 2024-12-07.

in.gov.br (Global: 3,151^st place; English: 5,932^nd place)

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

incb.org (Global: low place; English: 9,618^th place)

"International Narcotics Control Board Report 2012" (PDF). International Narcotics Control Board. 5 March 2013. p. 99. Archived (PDF) from the original on 18 August 2016. Retrieved 12 March 2016.

iwpharmacy.com (Global: low place; English: low place)

Byrne M, Pallaria F. "Dealing with Prescription Drug Shortages". www.iwpharmacy.com. Archived from the original on 2019-10-15. Retrieved 2019-10-15.

janssen.com (Global: low place; English: low place)

"Nucynta CR" (PDF). Janssen Inc. Archived (PDF) from the original on 2016-08-15. Retrieved 2016-06-21.

jnj.com (Global: low place; English: low place)

investor.jnj.com

"Janssen Pharmaceutica N.V. Announces Expansion of Licensing Agreement for Tapentadol". J&J Press Release. 7 June 2010. Archived from the original on 2018-09-23.

legislation.gov.uk (Global: 809^th place; English: 536^th place)

"The Misuse of Drugs Act 1971 (Amendment) Order 2011". www.legislation.gov.uk. Archived from the original on 2021-05-03. Retrieved 2011-03-26.

mayoclinic.org (Global: 1,610^th place; English: 1,279^th place)

"Tapentadol (oral route)". Mayo Clinic. Retrieved 2025-04-05.

medicinescomplete.com (Global: low place; English: low place)

Brayfield A, ed. (14 November 2011). "Tapentadol". Martindale: The Complete Drug Reference. Pharmaceutical Press. Archived from the original on 29 August 2021. Retrieved 2 April 2014.

medlineplus.gov (Global: 1,581^st place; English: 1,299^th place)

"Tapentadol". MedLine Plus. 2024-03-15. Retrieved 2024-11-25.

medscape.com (Global: 719^th place; English: 636^th place)

reference.medscape.com

"Medscape-Nucynta". Archived from the original on 2017-12-22. Retrieved 2012-12-09.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, et al. (January 2010). "Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies". Pharmacotherapy. 30 (1): 25–34. doi:10.1592/phco.30.1.25. PMC 2888545. PMID 20030470.
Khaja M, Lominadze G, Millerman K (July 2017). "Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review". The American Journal of Case Reports. 18: 817–821. doi:10.12659/AJCR.904695. PMC 5536129. PMID 28729524.
Alshehri FS (2023-03-01). "Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings". Drug Design, Development and Therapy. 17 (2023): 851–861. doi:10.2147/dddt.s402362. PMC 10039632. PMID 36974332.
Dart RC, Bartelson BB, Adams EH (August 2014). "Nonmedical use of tapentadol immediate release by college students". The Clinical Journal of Pain. 30 (8): 685–692. doi:10.1097/AJP.0000000000000001. PMID 24042351.
Singh DR, Nag K, Shetti AN, Krishnaveni N (July 2013). "Tapentadol hydrochloride: A novel analgesic". Saudi Journal of Anaesthesia. 7 (3): 322–326. doi:10.4103/1658-354X.115319. PMC 3757808. PMID 24015138.
Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C (2010). "Dose conversion between tapentadol immediate and extended release for low back pain". Pain Physician. 13 (1): 61–70. doi:10.36076/ppj.2010/13/61. PMID 20119464.
Chang EJ, Choi EJ, Kim KH (July 2016). "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?". The Korean Journal of Pain. 29 (3): 153–157. doi:10.3344/kjp.2016.29.3.153. PMC 4942642. PMID 27413479.
Guillén-Astete CA, Cardona-Carballo C, de la Casa-Resino C (November 2017). "Tapentadol versus tramadol in the management of low back pain in the emergency department: Impact of use on the need for reassessments". Medicine. 96 (45) e8403. doi:10.1097/MD.0000000000008403. PMC 5690718. PMID 29137025.
Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, et al. (July 2012). "Mechanistic and functional differentiation of tapentadol and tramadol". Expert Opinion on Pharmacotherapy. 13 (10): 1437–1449. doi:10.1517/14656566.2012.696097. PMID 22698264. S2CID 24226747.
Kathiresan P, Pakhre A, Kattula D, Sarkar S (October 2019). "Tapentadol Dependence: A Case Series". The Primary Care Companion for CNS Disorders. 21 (5): 23400. doi:10.4088/PCC.19l02444. PMID 31682335.
Polati E, Canonico PL, Schweiger V, Collino M (2019-05-16). "Tapentadol: an overview of the safety profile". Journal of Pain Research. 12: 1569–1576. doi:10.2147/JPR.S190154. PMC 6529613. PMID 31190968.
Roulet L, Rollason V, Desmeules J, Piguet V (July 2021). "Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients". Drugs. 81 (11): 1257–1272. doi:10.1007/s40265-021-01515-z. PMC 8318929. PMID 34196947.
Butler SF, McNaughton EC, Black RA (January 2015). "Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment". Pain Medicine. 16 (1): 119–130. doi:10.1111/pme.12524. PMID 25243972.
Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, et al. (April 2018). "Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System". The Journal of Pain. 19 (4): 439–453. doi:10.1016/j.jpain.2017.11.007. PMID 29224919.
Sharma M, Soni R (February 2018). "Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study". Scientific Reports. 8 (1) 2812. Bibcode:2018NatSR...8.2812S. doi:10.1038/s41598-018-21214-2. PMC 5809392. PMID 29434240.
Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I (January 2015). "Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain". Clinical Therapeutics. 37 (1): 94–113. doi:10.1016/j.clinthera.2014.07.005. PMID 25108647.
Vellucci R, Fornasari D (January 2023). "Appropriate use of tapentadol: focus on the optimal tapering strategy". Current Medical Research and Opinion. 39 (1): 123–129. doi:10.1080/03007995.2022.2148459. hdl:2434/948379. PMID 36427080.
Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, et al. (August 2014). "A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy". Diabetes Care. 37 (8): 2302–2309. doi:10.2337/dc13-2291. PMID 24848284.
Nossaman VE, Ramadhyani U, Kadowitz PJ, Nossaman BD (December 2010). "Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol". Anesthesiology Clinics. 28 (4): 647–666. doi:10.1016/j.anclin.2010.08.009. PMID 21074743.
Ramaswamy S, Chang S, Mehta V (May 2015). "Tapentadol--the evidence so far". Anaesthesia. 70 (5): 518–522. doi:10.1111/anae.13080. PMID 25866038.
Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T, et al. (April 2011). "Synergistic interaction between the two mechanisms of action of tapentadol in analgesia". The Journal of Pharmacology and Experimental Therapeutics. 337 (1): 312–320. doi:10.1124/jpet.110.175042. PMC 3364495. PMID 21262850.
Alshehri FS (2023). "Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings". Drug Design, Development and Therapy. 17: 851–861. doi:10.2147/DDDT.S402362. PMC 10039632. PMID 36974332.
Kokilambigai KS, Irina VM, Sheba Mariam KC, Adila K, Kathirvel S (September 2024). "Comprehensive overview of analytical and bioanalytical methodologies for the opioid analgesics - Tramadol and combinations". Anal Biochem. 692 115579. doi:10.1016/j.ab.2024.115579. PMID 38797485.
Chang EJ, Choi EJ, Kim KH (July 2016). "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?". The Korean Journal of Pain. 29 (3): 153–157. doi:10.3344/kjp.2016.29.3.153. PMC 4942642. PMID 27413479.
Herman TF, Cascella M, Muzio MR (2025). "Mu Receptors". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31855381. Retrieved 2025-04-06.
Roulet L, Rollason V, Desmeules J, Piguet V (July 2021). "Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients". Drugs. 81 (11): 1257–1272. doi:10.1007/s40265-021-01515-z. PMC 8318929. PMID 34196947.
Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ (May 2018). "Comparative pharmacology and toxicology of tramadol and tapentadol". European Journal of Pain. 22 (5): 827–844. doi:10.1002/ejp.1196. PMID 29369473.
Mateos RG, Bernal DS, Morera LM, Ferri CM, Escobar AE (January 2021). "Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release". Pain Physician. 24 (1): E75–E85. PMID 33400440.
Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K (2007). "Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects". European Journal of Drug Metabolism and Pharmacokinetics. 32 (3): 163–169. doi:10.1007/BF03190478. PMID 18062408.
Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS (2013-07-01). "Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects". Journal of Opioid Management. 9 (4): 291–300. doi:10.5055/jom.2013.0171. PMID 24353023.
Wiffen PJ, Derry S, Naessens K, Bell RF (September 2015). "Oral tapentadol for cancer pain". The Cochrane Database of Systematic Reviews. 2015 (9) CD011460. doi:10.1002/14651858.CD011460.pub2. PMC 6483480. PMID 26403220.
Vosburg SK, Beaumont J, Dailey-Govoni ST, Butler SF, Green JL (September 2020). "Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV)". Pain Medicine. 21 (9): 1891–1901. doi:10.1093/pm/pnz250. PMC 7553020. PMID 31617931.
Mukherjee D, Shukla L, Saha P, Mahadevan J, Kandasamy A, Chand P, et al. (March 2020). "Tapentadol abuse and dependence in India". Asian Journal of Psychiatry. 49 101978. doi:10.1016/j.ajp.2020.101978. PMID 32120298. S2CID 211834859. Archived from the original on 2021-12-20. Retrieved 2021-10-10.

ncbi.nlm.nih.gov

Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, et al. (January 2010). "Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies". Pharmacotherapy. 30 (1): 25–34. doi:10.1592/phco.30.1.25. PMC 2888545. PMID 20030470.
Khaja M, Lominadze G, Millerman K (July 2017). "Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review". The American Journal of Case Reports. 18: 817–821. doi:10.12659/AJCR.904695. PMC 5536129. PMID 28729524.
Alshehri FS (2023-03-01). "Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings". Drug Design, Development and Therapy. 17 (2023): 851–861. doi:10.2147/dddt.s402362. PMC 10039632. PMID 36974332.
Singh DR, Nag K, Shetti AN, Krishnaveni N (July 2013). "Tapentadol hydrochloride: A novel analgesic". Saudi Journal of Anaesthesia. 7 (3): 322–326. doi:10.4103/1658-354X.115319. PMC 3757808. PMID 24015138.
Chang EJ, Choi EJ, Kim KH (July 2016). "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?". The Korean Journal of Pain. 29 (3): 153–157. doi:10.3344/kjp.2016.29.3.153. PMC 4942642. PMID 27413479.
Guillén-Astete CA, Cardona-Carballo C, de la Casa-Resino C (November 2017). "Tapentadol versus tramadol in the management of low back pain in the emergency department: Impact of use on the need for reassessments". Medicine. 96 (45) e8403. doi:10.1097/MD.0000000000008403. PMC 5690718. PMID 29137025.
Polati E, Canonico PL, Schweiger V, Collino M (2019-05-16). "Tapentadol: an overview of the safety profile". Journal of Pain Research. 12: 1569–1576. doi:10.2147/JPR.S190154. PMC 6529613. PMID 31190968.
Roulet L, Rollason V, Desmeules J, Piguet V (July 2021). "Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients". Drugs. 81 (11): 1257–1272. doi:10.1007/s40265-021-01515-z. PMC 8318929. PMID 34196947.
Sharma M, Soni R (February 2018). "Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study". Scientific Reports. 8 (1) 2812. Bibcode:2018NatSR...8.2812S. doi:10.1038/s41598-018-21214-2. PMC 5809392. PMID 29434240.
Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T, et al. (April 2011). "Synergistic interaction between the two mechanisms of action of tapentadol in analgesia". The Journal of Pharmacology and Experimental Therapeutics. 337 (1): 312–320. doi:10.1124/jpet.110.175042. PMC 3364495. PMID 21262850.
Alshehri FS (2023). "Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings". Drug Design, Development and Therapy. 17: 851–861. doi:10.2147/DDDT.S402362. PMC 10039632. PMID 36974332.
Chang EJ, Choi EJ, Kim KH (July 2016). "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?". The Korean Journal of Pain. 29 (3): 153–157. doi:10.3344/kjp.2016.29.3.153. PMC 4942642. PMID 27413479.
Herman TF, Cascella M, Muzio MR (2025). "Mu Receptors". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31855381. Retrieved 2025-04-06.
Roulet L, Rollason V, Desmeules J, Piguet V (July 2021). "Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients". Drugs. 81 (11): 1257–1272. doi:10.1007/s40265-021-01515-z. PMC 8318929. PMID 34196947.
Wiffen PJ, Derry S, Naessens K, Bell RF (September 2015). "Oral tapentadol for cancer pain". The Cochrane Database of Systematic Reviews. 2015 (9) CD011460. doi:10.1002/14651858.CD011460.pub2. PMC 6483480. PMID 26403220.
Vosburg SK, Beaumont J, Dailey-Govoni ST, Butler SF, Green JL (September 2020). "Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV)". Pain Medicine. 21 (9): 1891–1901. doi:10.1093/pm/pnz250. PMC 7553020. PMID 31617931.

dailymed.nlm.nih.gov

Drug Enforcement Agency (US) (2019-09-18). "Label: Nucynta - Tapentadol hydrochloride tablet, film coated". DailyMed. Retrieved 2024-11-24.
"Nucynta 50 mg". dailymed.nlm.nih.gov. Retrieved 2024-12-07.

pubchem.ncbi.nlm.nih.gov

"Tapentadol". PubChem. U.S. National Library of Medicine. Archived from the original on August 9, 2016. Retrieved June 14, 2016. This article incorporates text from this source, which is in the public domain.

nps.org.au (Global: low place; English: low place)

"Tapentadol Consumer Medicine Information". NPS MedicineWise. September 2020 – via nps.org.au.
"5 steps to tapering opioids for patients with chronic non-cancer pain". NPS MedicineWise. 2020-01-31. Retrieved 2025-04-05.

nsw.gov.au (Global: 640^th place; English: 382^nd place)

health.nsw.gov.au

"Schedule 8 Medicines". Health NSW. 2024. Retrieved 21 November 2024.

osf.io (Global: 7,153^rd place; English: 4,975^th place)

Mukherjee D, Shukla L, Saha P, Mahadevan J, Kandasamy A, Chand P, et al. (March 2020). "Tapentadol abuse and dependence in India". Asian Journal of Psychiatry. 49 101978. doi:10.1016/j.ajp.2020.101978. PMID 32120298. S2CID 211834859. Archived from the original on 2021-12-20. Retrieved 2021-10-10.

patents.google.com (Global: 1,182^nd place; English: 725^th place)

US 6248737, Buschmann H, Strassburger W, Friderichs E, "1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects", issued 19 June 2001, assigned to Gruenenthal GmbH

prnewswire.co.uk (Global: 6,376^th place; English: 4,260^th place)

"Grünenthal GmbH Presents Tapentadol, a Novel Centrally Acting Analgesic, at the 25th Annual Scientific Meeting of The American Pain Society". PR Newswire. 6 June 2006. Archived from the original on 2012-02-07. Retrieved 2007-09-20.

psychiatrist.com (Global: low place; English: low place)

"Tapentadol Dependence: A Case Series". Psychiatrist.com. Retrieved 2025-04-05.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, et al. (July 2012). "Mechanistic and functional differentiation of tapentadol and tramadol". Expert Opinion on Pharmacotherapy. 13 (10): 1437–1449. doi:10.1517/14656566.2012.696097. PMID 22698264. S2CID 24226747.
Mukherjee D, Shukla L, Saha P, Mahadevan J, Kandasamy A, Chand P, et al. (March 2020). "Tapentadol abuse and dependence in India". Asian Journal of Psychiatry. 49 101978. doi:10.1016/j.ajp.2020.101978. PMID 32120298. S2CID 211834859. Archived from the original on 2021-12-20. Retrieved 2021-10-10.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Australian Public Assessment Report for Tapentadol" (PDF). Therapeutic Goods Administration. February 2011. Archived from the original on 23 September 2018. Retrieved 12 March 2016.

thepharmaletter.com (Global: low place; English: low place)

Staff (16 January 2015). "Depomed pays over $1 billion for US rights to Janssen's Nucynta franchise". The Pharma Letter. Archived from the original on 2016-03-08.

unsw.edu.au (Global: 4,584^th place; English: 3,029^th place)

"Tapentadol use and harms in Australia: Analysis of opioid sales data and sentinel survey data from people who inject drugs". UNSW Sites. 2020-06-23. Retrieved 2025-04-02.

usdoj.gov (Global: 2,755^th place; English: 1,753^rd place)

deadiversion.usdoj.gov

"DEA Diversion Control – Controlled Substances Schedules". US Federal Government. Archived from the original on 2021-04-25. Retrieved 2012-05-16.
"2014 - Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014". Deadiversion.usdoj.gov. Archived from the original on 2016-03-04. Retrieved 2018-09-22.

web.archive.org (Global: 1^st place; English: 1^st place)

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
"Active substance(s): tapentadol" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 21 July 2022. Archived (PDF) from the original on 2022-09-06. Retrieved 2022-09-06.
Brayfield A, ed. (14 November 2011). "Tapentadol". Martindale: The Complete Drug Reference. Pharmaceutical Press. Archived from the original on 29 August 2021. Retrieved 2 April 2014.
"Nucynta History". drugs.com. Archived from the original on April 12, 2015. Retrieved April 5, 2015.
"Medscape-Nucynta". Archived from the original on 2017-12-22. Retrieved 2012-12-09.
"Nucynta Label" (PDF). Archived from the original (PDF) on 2021-03-30.
"Nucynta CR" (PDF). Janssen Inc. Archived (PDF) from the original on 2016-08-15. Retrieved 2016-06-21.
35th Expert Committee on Drug Dependence, Hammamet, Tunisia (June 2012). "Tapentadol: Expert peer review on pre-review report" (PDF). World Health Organization. Archived (PDF) from the original on 16 March 2014. Retrieved 16 March 2014.
"DEA Diversion Control – Controlled Substances Schedules". US Federal Government. Archived from the original on 2021-04-25. Retrieved 2012-05-16.
"2014 - Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014". Deadiversion.usdoj.gov. Archived from the original on 2016-03-04. Retrieved 2018-09-22.
"Tapentadol". PubChem. U.S. National Library of Medicine. Archived from the original on August 9, 2016. Retrieved June 14, 2016. This article incorporates text from this source, which is in the public domain.
"Grünenthal GmbH Presents Tapentadol, a Novel Centrally Acting Analgesic, at the 25th Annual Scientific Meeting of The American Pain Society". PR Newswire. 6 June 2006. Archived from the original on 2012-02-07. Retrieved 2007-09-20.
"Janssen Pharmaceutica N.V. Announces Expansion of Licensing Agreement for Tapentadol". J&J Press Release. 7 June 2010. Archived from the original on 2018-09-23.
Dutton G (1 June 2012). "Pain Management Market Ripe with Immediate Opportunities". Genetic Engineering & Biotechnology News. Archived from the original on 2018-09-23.
"Nucynta (tapentadol) FDA Approval History – Drugs.com". www.drugs.com. Archived from the original on 2015-04-12. Retrieved 2016-03-09.
"FDA Approves Nucynta ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". Archived from the original on 2021-03-05. Retrieved 2018-01-23.
Staff (16 January 2015). "Depomed pays over $1 billion for US rights to Janssen's Nucynta franchise". The Pharma Letter. Archived from the original on 2016-03-08.
Byrne M, Pallaria F. "Dealing with Prescription Drug Shortages". www.iwpharmacy.com. Archived from the original on 2019-10-15. Retrieved 2019-10-15.
"Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs". FiercePharma. 5 December 2017. Archived from the original on 2019-10-15. Retrieved 2019-10-15.
"Supplemental data for World Health Organization (Expert Committee on Drug Dependence) Critical Review on drug dependence of tapentadol" (PDF). World Health Organization. 23 May 2014. p. 18. Archived (PDF) from the original on 29 August 2021. Retrieved 12 March 2014.
"World Health Organization: Reports of advisory bodies" (PDF). World Health Organization. 22 January 2015. pp. 2, 4. Archived (PDF) from the original on 8 September 2015. Retrieved 12 March 2016.
"Australian Public Assessment Report for Tapentadol" (PDF). Therapeutic Goods Administration. February 2011. Archived from the original on 23 September 2018. Retrieved 12 March 2016.
"The Misuse of Drugs Act 1971 (Amendment) Order 2011". www.legislation.gov.uk. Archived from the original on 2021-05-03. Retrieved 2011-03-26.
"International Narcotics Control Board Report 2012" (PDF). International Narcotics Control Board. 5 March 2013. p. 99. Archived (PDF) from the original on 18 August 2016. Retrieved 12 March 2016.
"Canada Gazette – Regulations Amending the Narcotic Control Regulations (Tapentadol) – (Archived)". Canada Gazette. Government of Canada, Public Works and Government Services Canada, Public Services and Procurement Canada, Integrated Services Branch, Canada. 29 July 2015. Archived from the original on 2016-03-13. Retrieved 2016-03-12.
Mukherjee D, Shukla L, Saha P, Mahadevan J, Kandasamy A, Chand P, et al. (March 2020). "Tapentadol abuse and dependence in India". Asian Journal of Psychiatry. 49 101978. doi:10.1016/j.ajp.2020.101978. PMID 32120298. S2CID 211834859. Archived from the original on 2021-12-20. Retrieved 2021-10-10.
"71 arrested in DMP's anti-narcotics drive". BanglaNews24.com (in Bengali). 2021-12-14. Archived from the original on 2021-12-30. Retrieved 2021-12-30.

wfsahq.org (Global: low place; English: low place)

resources.wfsahq.org

"Tramadol and Tapentadol: Clinical and Pharmacologic Review". WFSA Resource Library. Retrieved 2025-04-02.

who.int (Global: 195^th place; English: 302^nd place)

who.int

35th Expert Committee on Drug Dependence, Hammamet, Tunisia (June 2012). "Tapentadol: Expert peer review on pre-review report" (PDF). World Health Organization. Archived (PDF) from the original on 16 March 2014. Retrieved 16 March 2014.
"Supplemental data for World Health Organization (Expert Committee on Drug Dependence) Critical Review on drug dependence of tapentadol" (PDF). World Health Organization. 23 May 2014. p. 18. Archived (PDF) from the original on 29 August 2021. Retrieved 12 March 2014.

apps.who.int

"World Health Organization: Reports of advisory bodies" (PDF). World Health Organization. 22 January 2015. pp. 2, 4. Archived (PDF) from the original on 8 September 2015. Retrieved 12 March 2016.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Oliveira M, Moisés MC, Dias EC, dos Santos MV, Schmidt AP (January 2024). "Treatment-emergent adverse events of tapentadol or oxycodone in pain management after orthopedic surgeries: A systematic review and meta-analysis of randomized clinical trials". JCA Advances. 1 (3) 100024. doi:10.1016/j.jcadva.2024.100024. ISSN 2950-5534.

Tapentadol (English Wikipedia)

banglanews24.com (Global: 4,869th place; English: 6,845th place)

books.google.com (Global: 3rd place; English: 3rd place)

cdc.gov (Global: 218th place; English: 212th place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

fiercepharma.com (Global: low place; English: 8,921st place)

gazette.gc.ca (Global: low place; English: low place)

genengnews.com (Global: low place; English: 6,625th place)

gov.uk (Global: 432nd place; English: 278th place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

healthdirect.gov.au (Global: low place; English: low place)

in.gov.br (Global: 3,151st place; English: 5,932nd place)

incb.org (Global: low place; English: 9,618th place)

iwpharmacy.com (Global: low place; English: low place)

janssen.com (Global: low place; English: low place)

jnj.com (Global: low place; English: low place)

investor.jnj.com

legislation.gov.uk (Global: 809th place; English: 536th place)

mayoclinic.org (Global: 1,610th place; English: 1,279th place)

medicinescomplete.com (Global: low place; English: low place)

medlineplus.gov (Global: 1,581st place; English: 1,299th place)

medscape.com (Global: 719th place; English: 636th place)

reference.medscape.com

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

nps.org.au (Global: low place; English: low place)

nsw.gov.au (Global: 640th place; English: 382nd place)

health.nsw.gov.au

osf.io (Global: 7,153rd place; English: 4,975th place)

patents.google.com (Global: 1,182nd place; English: 725th place)

prnewswire.co.uk (Global: 6,376th place; English: 4,260th place)

psychiatrist.com (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

thepharmaletter.com (Global: low place; English: low place)

unsw.edu.au (Global: 4,584th place; English: 3,029th place)

usdoj.gov (Global: 2,755th place; English: 1,753rd place)

deadiversion.usdoj.gov

web.archive.org (Global: 1st place; English: 1st place)

wfsahq.org (Global: low place; English: low place)

resources.wfsahq.org

who.int (Global: 195th place; English: 302nd place)

who.int

apps.who.int

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

banglanews24.com (Global: 4,869^th place; English: 6,845^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

cdc.gov (Global: 218^th place; English: 212^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

genengnews.com (Global: low place; English: 6,625^th place)

gov.uk (Global: 432^nd place; English: 278^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

in.gov.br (Global: 3,151^st place; English: 5,932^nd place)

incb.org (Global: low place; English: 9,618^th place)

legislation.gov.uk (Global: 809^th place; English: 536^th place)

mayoclinic.org (Global: 1,610^th place; English: 1,279^th place)

medlineplus.gov (Global: 1,581^st place; English: 1,299^th place)

medscape.com (Global: 719^th place; English: 636^th place)

nih.gov (Global: 4^th place; English: 4^th place)

nsw.gov.au (Global: 640^th place; English: 382^nd place)

osf.io (Global: 7,153^rd place; English: 4,975^th place)

patents.google.com (Global: 1,182^nd place; English: 725^th place)

prnewswire.co.uk (Global: 6,376^th place; English: 4,260^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

unsw.edu.au (Global: 4,584^th place; English: 3,029^th place)

usdoj.gov (Global: 2,755^th place; English: 1,753^rd place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 195^th place; English: 302^nd place)

worldcat.org (Global: 5^th place; English: 5^th place)